Droice

Executive Summary

Droice Labs is a New York-based AI/ML company that has developed Hawk, a regulatory-grade middleware platform designed to losslessly convert messy real-world data (RWD) from sources like EHRs, labs, and claims into analysis-ready formats for clinical trials and real-world evidence generation. Founded in 2017, the company addresses a critical bottleneck in life sciences: the fragmentation and inconsistency of healthcare data. Hawk ensures data traceability and quality, enabling faster, leaner trials and more robust evidence. By automating data processing and maintaining regulatory compliance, Droice helps sponsors reduce trial timelines and costs while improving data integrity. The market for RWD processing is expanding rapidly, driven by regulatory acceptance of real-world evidence and the need for decentralized trials. Droice competes with other data platforms and consultancies, but its focus on lossless conversion and regulatory-grade output positions it well. The company is privately held and has not publicly disclosed funding; however, its technology has potential for wide adoption among CROs, biopharma, and academic research centers. Near-term catalysts include new product features, partnerships with major pharma, and a likely Series A fundraising round. With a strong value proposition and growing market demand, Droice is poised for growth in the evolving clinical trial landscape.

Upcoming Catalysts (preview)

• Q3 2026Launch of enhanced Hawk platform with new data sources70% success
• Q4 2026Strategic partnership with top 10 pharma company for RWD integration50% success
• Q2 2026Announcement of Series A funding round60% success